Comparison of long-term usefulness of clopidogrel therapy after the first percutaneous coronary intervention or coronary artery bypass grafting versus that after the second or repeat intervention

Jacqueline Saw; Eric J Topol; Steven R Steinhubl; Danielle Brennan; Peter B Berger; David J Moliterno; CREDO Investigators

doi:10.1016/j.amjcard.2004.05.026

Comparison of long-term usefulness of clopidogrel therapy after the first percutaneous coronary intervention or coronary artery bypass grafting versus that after the second or repeat intervention

Am J Cardiol. 2004 Sep 1;94(5):623-5. doi: 10.1016/j.amjcard.2004.05.026.

Authors

Jacqueline Saw¹, Eric J Topol, Steven R Steinhubl, Danielle Brennan, Peter B Berger, David J Moliterno; CREDO Investigators

Affiliation

¹ Department of Cardiovascular Medicine, the Cleveland Clinic Foundation, Cleveland, Ohio, USA.

PMID: 15342293
DOI: 10.1016/j.amjcard.2004.05.026

Abstract

Patients in the Clopidogrel for the Reduction of Events During Observation trial were subgrouped according to whether they underwent index percutaneous coronary artery revascularization procedures only or this procedure plus subsequent percutaneous or surgical revascularization procedures during 1-year follow-up. The relative risk reduction in ischemic events associated with up-front and long-term clopidogrel compared with placebo was 2-fold greater in patients who required repeat revascularization procedures compared with those who did not (42.4% vs 21.7%).

Publication types

Comparative Study
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Angioplasty, Balloon, Coronary / methods*
Clopidogrel
Coronary Artery Bypass / methods*
Female
Humans
Male
Middle Aged
Myocardial Ischemia / therapy*
Platelet Aggregation Inhibitors / therapeutic use*
Randomized Controlled Trials as Topic
Reoperation
Risk Reduction Behavior
Ticlopidine / analogs & derivatives*
Ticlopidine / therapeutic use*

Substances

Platelet Aggregation Inhibitors
Clopidogrel
Ticlopidine